FIG 4.

Definition of a molecular classification on augmented synthetic MDS cohort starting from 944 patients available in 2014, as performed in setting C. (A) Evaluation of the real (blue) and synthetic (red) patients' distribution considering genomic groups classification. (B) Genomic group definition according to Bersanelli et al.²⁰ (C) SHAP summary plot analysis on the top 10 most important features for a real test set, a synthetic test set, and a complete augmented synthetic data set for the genomic group 6. Below is the force plot showing the importance of the most relevant features in assigning a synthetic patient to genomic group 2. MDS, myelodysplastic syndromes; SHAP, Shapley Additive Explanations.